BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23665201)

  • 21. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.
    Xia L; Mo P; Huang W; Zhang L; Wang Y; Zhu H; Tian D; Liu J; Chen Z; Zhang Y; Chen Z; Hu H; Fan D; Nie Y; Wu K
    Carcinogenesis; 2012 Nov; 33(11):2250-9. PubMed ID: 22831955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
    Gayle SS; Castellino RC; Buss MC; Nahta R
    Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
    Minami T; Adachi M; Kawamura R; Zhang Y; Shinomura Y; Imai K
    Clin Cancer Res; 2005 Jul; 11(14):5248-56. PubMed ID: 16033843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
    Papageorgiou A; Kamat A; Benedict WF; Dinney C; McConkey DJ
    Mol Cancer Ther; 2006 Dec; 5(12):3032-41. PubMed ID: 17172406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ
    Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
    Wang M; Gartel AL
    Cancer Biol Ther; 2012 Feb; 13(3):184-9. PubMed ID: 22353937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS.
    Halasi M; Váraljai R; Benevolenskaya E; Gartel AL
    J Biol Chem; 2016 Jan; 291(1):142-8. PubMed ID: 26559972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1.
    Radhakrishnan SK; Bhat UG; Hughes DE; Wang IC; Costa RH; Gartel AL
    Cancer Res; 2006 Oct; 66(19):9731-5. PubMed ID: 17018632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3,3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1.
    Ahmad A; Ali S; Wang Z; Ali AS; Sethi S; Sakr WA; Raz A; Rahman KM
    Int J Cancer; 2011 Oct; 129(7):1781-91. PubMed ID: 21154750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FoxM1 is a general target for proteasome inhibitors.
    Bhat UG; Halasi M; Gartel AL
    PLoS One; 2009 Aug; 4(8):e6593. PubMed ID: 19672316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
    Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
    Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts.
    Wang M; Gartel AL
    Mol Cancer Ther; 2011 Dec; 10(12):2287-97. PubMed ID: 21903609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
    Martin SM; Churchill E; McKnight H; Mahaffey CM; Ma Y; O'Donnell RT; Tuscano JM
    J Hematol Oncol; 2011 Dec; 4():49. PubMed ID: 22128838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer.
    Yoshida Y; Wang IC; Yoder HM; Davidson NO; Costa RH
    Gastroenterology; 2007 Apr; 132(4):1420-31. PubMed ID: 17408638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.